---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-099534"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2025-10-15T23:59:59+00:00"
generated_at: "2026-05-17T03:46:39.917098+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea sets ATRN-119 RP2D at 1,100 mg QD; pauses monotherapy; prioritizes WEE1 inhibitor APR-1051

## Summary
- RP2D of 1,100 mg once daily identified for ATRN-119 from ABOYA-119 Phase 1/2a study.
- Further enrollment paused in both QD and BID monotherapy arms; currently-dosed patients continue without interruption.
- Considering combination with radiation (HPV+ head & neck), ADCs, and checkpoint inhibitors; discussions with academic centers.
- Lead WEE1 inhibitor APR-1051 advancing; Phase 1 data expected at AACR-NCI-EORTC conference on Oct 24, 2025.
- ATRN-119 showed durable disease stabilization, manageable AEs, dose-proportional PK at RP2D.

## SEC filing metadata
- accession: 0001104659-25-099534
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2025-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465925099534/0001104659-25-099534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465925099534/apre-20251015x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-099534
- JSON: https://secwatch.observer/filing/0001104659-25-099534.json
- Plain text: https://secwatch.observer/filing/0001104659-25-099534.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.